Analyst Research Report Snapshot

Title:

Glenmark Pharmaceuticals | Concall Update

Price:

$46.00

Provider:

IndiaNivesh Securities Pvt Ltd

Date:

30 Jan 2013

Pages:

5

Type:

AcrobatPDF

Companies referenced:

GLEN.NS

Available for Immediate Download
Summary:

Glenmark Pharmaceuticals Ltd.|Q3FY13 Concall Update Adjusted numbers were slightly above estimates: Adjusting for out-licensing income of Rs 493 million in Q3FY13 & Rs 238 million in Q3FY12 and for forex gain of Rs 40 million in Q3FY13 (reported in other expenditure) & against forex loss of Rs 1.02 billion in Q3FY12 (forex gain of Rs 150 million in Q2FY13) , Glenmark’s reported financials were slightly above our estimates. Revenue grew 32.2% y-o-y to Rs 13.32 billion (INSPL est = 12.76 billion), EBITDA grew 47.4% y-o-y to Rs 2.67 billion (V/s INSPL est= Rs 2.59 billion) and net profit grew 30% y-o-y to 1.60 billion (V/s INSPL est=Rs 1.47 billion). EBITDA margins increased ~200 bps y-o-y (declined 38 bps q-o-q) to 20% level (V/s INSPL est= 20.3%). Outlook & Valuations: Considering the revenue growth of the company in last few quarters and ramp up in US business, we are of the view that company would carry same growth momentum going forward. Further, new launches, including Mupirocin Calcium Cream & 180 day’s exclusivity of Lipocream are likely to maintain the growth momentum in US market. In 9MFY13 company has received out licensing income of Rs 493 million from Forest Lab. Likely withdrawal of Revamilast from NCE pipeline may have negative sentiments for R&D efforts of the company. We expect company to clock core business revenue of 26% CAGR over FY12-FY14E (excluding out-licensing income) to post revenue of Rs 58.80 billion in FY14E. core net profit is expected to grow above 35% CAGR over the same period to report PAT of Rs 7.23 billion in FY14E. We expect company to Report adj EPS of Rs 20.64 in FY13E & Rs 26.64 in FY14E. At CMP of Rs 490, the stock is trading at P/E multiple of 23.7x & 18.4x of FY13E & FY14E earnings estimates respectively. Earlier we had buy recommendation on the stock with the target price of Rs 465 which has been achieved. Currently we recommend to HOLD on the stock with the target Price of Rs 506. (Valuing at 19x of FY14E earnings estimates).

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.